← 返回

靶向解整合素金属蛋白酶 (ADAM) 17-CD122 轴增强 CD8⁺ T 细胞效应分化与抗肿瘤免疫

英文原题:Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8(+) T cell effector differentiation and anti-tumor immunity.

查看英文原题

Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8(+) T cell effector differentiation and anti-tumor immunity.

PubMed 2024/06/26(内容时间) Signal Transduct Target Ther Q1 · IF 81.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD8阳性T细胞免疫反应受多层网络调控,但其翻译后调节仍知之甚少。跨膜蛋白胞外结构域脱落可通过蛋白水解调节受体表达和信号转导。本研究靶向脱落酶ADAM17,揭示了CD8阳性T细胞中由胞外结构域脱落介导的翻译后调控机制。转录组和蛋白组分析显示该机制参与CD8阳性T细胞调控。T细胞特异性敲除ADAM17显著促进效应CD8阳性T细胞分化,并增强其清除病原体和肿瘤的细胞毒作用。机制上,ADAM17切割膜蛋白CD122;抑制ADAM17可提高小鼠和人CD8阳性T细胞的CD122表达,增强对IL-2和IL-15的反应。抑制ADAM17还可提高实体瘤CAR-T 疗效。结果揭示重要翻译后调控机制,并提示靶向ADAM17可成为增强抗肿瘤免疫的潜在策略。

展开英文摘要原文

CD8 + T cell immune responses are regulated by multi-layer networks, while the post-translational regulation remains largely unknown. Transmembrane ectodomain shedding is an important post-translational process orchestrating receptor expression and signal transduction through proteolytic cleavage of membrane proteins.

Here, by targeting the sheddase A Disintegrin and Metalloprotease (ADAM)17, we defined a post-translational regulatory mechanism mediated by the ectodomain shedding in CD8 + T cells. Transcriptomic and proteomic analysis revealed the involvement of post-translational regulation in CD8 + T cells. T cell-specific deletion of ADAM17 led to a dramatic increase in effector CD8 + T cell differentiation and enhanced cytolytic effects to eliminate pathogens and tumors.

Mechanistically, ADAM17 regulated CD8 + T cells through cleavage of membrane CD122. ADAM17 inhibition led to elevated CD122 expression and enhanced response to IL-2 and IL-15 stimulation in both mouse and human CD8 + T cells. Intriguingly, inhibition of ADAM17 in CD8 + T cells improved the efficacy of chimeric antigen receptor (CAR) T cells in solid tumors.

Our findings reveal a critical post-translational regulation in CD8 + T cells, providing a potential therapeutic strategy of targeting ADAM17 for effective anti-tumor immunity.

论文信息

作者
Sun L、Jiao A、Liu H、Ding R、Yuan N、Yang B、Zhang C、Jia X
第一作者单位
Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.China
通讯作者单位
Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. bj.zhang@mail.xjtu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Signal transduction and targeted therapy2024 Jun 26
原文标识
PubMed 38918390 · DOI 10.1038/s41392-024-01873-6